Comparison of 18F-dopa PET/CT and 123I-MIBG Scintigraphy in Stage 3 and 4 Neuroblastoma: a Pilot Study

Overview

Journal Eur J Nucl Med Mol Imaging

Specialties Biophysics
Nuclear Medicine
Radiology

Date 2011 Sep 21

PMID 21932116

Citations 35

Authors

Arnoldo Piccardo

Egesta Lopci

Massimo Conte

Alberto Garaventa

Luca Foppiani

Vania Altrinetti

Cristina Nanni

Pietro Bianchi

Angela Cistaro

Stefania Sorrentino

Manlio Cabria

Andrea Pession

Matteo Puntoni

Giampiero Villavecchia

Stefano Fanti

Affiliations

Soon will be listed here.

Abstract

Purpose: (18)F-Dopa positron emission tomography (PET)/CT has proved a valuable tool for the assessment of neuroendocrine tumours. So far no data are available on (18)F-dopa utilization in neuroblastoma (NB). Our aim was to evaluate the role of (18)F-dopa PET/CT in NB and compare its diagnostic value with that of (123)I-metaiodobenzylguanidine (MIBG) scintigraphy in patients affected by stage 3-4 NB.

Methods: We prospectively evaluated 28 paired (123)I-MIBG and (18)F-dopa PET/CT scans in 19 patients: 4 at the time of the NB diagnosis and 15 when NB relapse was suspected. For both imaging modalities we performed a scan-based and a lesion-based analysis and calculated sensitivity, specificity and accuracy. The standard of reference was based on clinical, imaging and histological data.

Results: NB localizations were confirmed in 17 of 19 patients. (18)F-Dopa PET/CT and (123)I-MIBG scintigraphy properly detected disease in 16 (94%) and 11 (65%), respectively. On scan-based analysis, (18)F-dopa PET/CT showed a sensitivity and accuracy of 95 and 96%, respectively, while (123)I-MIBG scanning showed a sensitivity and accuracy of 68 and 64%, respectively (p < 0.05). No significant difference in terms of specificity was found. In 9 of 28 paired scans (32%) PET/CT results influenced the patient management. We identified 156 NB localizations, 141 of which were correctly detected by (18)F-dopa PET/CT and 88 by MIBG. On lesion-based analysis, (18)F-dopa PET/CT showed a sensitivity and accuracy of 90% whereas (123)I-MIBG scintigraphy showed a sensitivity and accuracy of 56 and 57%, respectively (p < 0.001). No significant difference in terms of specificity was found.

Conclusion: In our NB population (18)F-dopa PET/CT displayed higher overall accuracy than (123)I-MIBG scintigraphy. Consequently, we suggest (18)F-dopa PET/CT as a new opportunity for NB assessment.

Citing Articles

Recommendations for the use of nuclear medicine imaging in patients with neuroblastoma.

Sanchez-Vano R, Balaguer J, Borrego-Dorado I, Esteban-Figueruelo A, Gamez C, Hladun R Clin Transl Oncol. 2024; .

PMID: 39508974 DOI: 10.1007/s12094-024-03755-3.

The prognostic role of F-FDG PET/CT-based response evaluation in children with stage 4 neuroblastoma.

Lu X, Li C, Wang S, Yin Y, Fu H, Wang H Eur Radiol. 2024; 34(11):7125-7135.

PMID: 38758254 DOI: 10.1007/s00330-024-10781-w.

Predictive value of 18 F-FDG PET/CT versus bone marrow biopsy and aspiration in pediatric neuroblastoma.

Zhao Z, Yang C Clin Exp Metastasis. 2024; 41(5):627-638.

PMID: 38609536 DOI: 10.1007/s10585-024-10286-2.

The evidence-based role of catecholaminergic PET tracers in Neuroblastoma. A systematic review and a head-to-head comparison with mIBG scintigraphy.

Piccardo A, Treglia G, Fiz F, Bar-Sever Z, Bottoni G, Biassoni L Eur J Nucl Med Mol Imaging. 2023; 51(3):756-767.

PMID: 37962616 PMC: 10796700. DOI: 10.1007/s00259-023-06486-9.

An overview of radiolabeled amino acid tracers in oncologic imaging.

Jain S, Dhingra V Front Oncol. 2023; 13:983023.

PMID: 36874105 PMC: 9981995. DOI: 10.3389/fonc.2023.983023.

References

Frappaz D, Bonneu A, Chauvot P, Edeline V, Giammarile F, Siles S . Metaiodobenzylguanidine assessment of metastatic neuroblastoma: observer dependency and chemosensitivity evaluation. The SFOP Group. Med Pediatr Oncol. 2000; 34(4):237-41. DOI: 10.1002/(sici)1096-911x(200004)34:4<237::aid-mpo1>3.0.co;2-j. View

Okuyama C, Ushijima Y, Kubota T, Nakamura T, Kikkawa M, Nishimura T . Utility of follow-up studies using meta-[123 I]iodobenzylguanidine scintigraphy for detecting recurrent neuroblastoma. Nucl Med Commun. 2002; 23(7):663-72. DOI: 10.1097/00006231-200207000-00011. View

Schwarz K, Driver I, Lewis I, Taylor R . Positive MIBG scanning at the time of relapse in neuroblastoma which was MIBG negative at diagnosis. Br J Radiol. 1997; 70:90-2. DOI: 10.1259/bjr.70.829.9059302. View

Biasotti S, Garaventa A, Villavecchia G, Cabria M, Nantron M, De Bernardi B . False-negative metaiodobenzylguanidine scintigraphy at diagnosis of neuroblastoma. Med Pediatr Oncol. 2000; 35(2):153-5. DOI: 10.1002/1096-911x(200008)35:2<153::aid-mpo18>3.0.co;2-7. View

Hoefnagel C, VOUTE P, de Kraker J, MARCUSE H . Radionuclide diagnosis and therapy of neural crest tumors using iodine-131 metaiodobenzylguanidine. J Nucl Med. 1987; 28(3):308-14. View

Messina J, Cheng S, Franc B, Charron M, Shulkin B, To B . Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma. Pediatr Blood Cancer. 2006; 47(7):865-74. DOI: 10.1002/pbc.20777. View

Taggart D, Han M, Quach A, Groshen S, Ye W, Villablanca J . Comparison of iodine-123 metaiodobenzylguanidine (MIBG) scan and [18F]fluorodeoxyglucose positron emission tomography to evaluate response after iodine-131 MIBG therapy for relapsed neuroblastoma. J Clin Oncol. 2009; 27(32):5343-9. PMC: 2773221. DOI: 10.1200/JCO.2008.20.5732. View

Geatti O, Shapiro B, Sisson J, Hutchinson R, Mallette S, Eyre P . Iodine-131 metaiodobenzylguanidine scintigraphy for the location of neuroblastoma: preliminary experience in ten cases. J Nucl Med. 1985; 26(7):736-42. View

Melzer H, Coppenrath E, Schmid I, Albert M, von Schweinitz D, Tudball C . ¹²³I-MIBG scintigraphy/SPECT versus ¹⁸F-FDG PET in paediatric neuroblastoma. Eur J Nucl Med Mol Imaging. 2011; 38(9):1648-58. DOI: 10.1007/s00259-011-1843-8. View

10.

Hoegerle S, Altehoefer C, Ghanem N, Koehler G, Waller C, Scheruebl H . Whole-body 18F dopa PET for detection of gastrointestinal carcinoid tumors. Radiology. 2001; 220(2):373-80. DOI: 10.1148/radiology.220.2.r01au25373. View

11.

Hoegerle S, Altehoefer C, Ghanem N, Brink I, Moser E, Nitzsche E . 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med. 2001; 28(1):64-71. DOI: 10.1007/s002590000404. View

12.

Bonnin F, Lumbroso J, Tenenbaum F, Hartmann O, Parmentier C . Refining interpretation of MIBG scans in children. J Nucl Med. 1994; 35(5):803-10. View

13.

Monclair T, Brodeur G, Ambros P, Brisse H, Cecchetto G, Holmes K . The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol. 2008; 27(2):298-303. PMC: 2650389. DOI: 10.1200/JCO.2008.16.6876. View

14.

Giammarile F, Lumbroso J, Ricard M, Aubert B, Hartmann O, Schlumberger M . Radioiodinated metaiodobenzylguanidine in neuroblastoma: influence of high dose on tumour site detection. Eur J Nucl Med. 1995; 22(10):1180-3. DOI: 10.1007/BF00800601. View

15.

Hoegerle S, Nitzsche E, Altehoefer C, Ghanem N, Manz T, Brink I . Pheochromocytomas: detection with 18F DOPA whole body PET--initial results. Radiology. 2002; 222(2):507-12. DOI: 10.1148/radiol.2222010622. View

16.

Timmers H, Chen C, Carrasquillo J, Whatley M, Ling A, Havekes B . Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. J Clin Endocrinol Metab. 2009; 94(12):4757-67. PMC: 2795662. DOI: 10.1210/jc.2009-1248. View

17.

Mc Dowell H, Losty P, Barnes N, Kokai G . Utility of FDG-PET/CT in the follow-up of neuroblastoma which became MIBG-negative. Pediatr Blood Cancer. 2008; 52(4):552. DOI: 10.1002/pbc.21859. View

18.

Sharp S, Shulkin B, Gelfand M, Salisbury S, Furman W . 123I-MIBG scintigraphy and 18F-FDG PET in neuroblastoma. J Nucl Med. 2009; 50(8):1237-43. DOI: 10.2967/jnumed.108.060467. View

19.

Shulkin B, Hutchinson R, Castle V, Yanik G, Shapiro B, Sisson J . Neuroblastoma: positron emission tomography with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose compared with metaiodobenzylguanidine scintigraphy. Radiology. 1996; 199(3):743-50. DOI: 10.1148/radiology.199.3.8637999. View

20.

Vik T, Pfluger T, Kadota R, Castel V, Tulchinsky M, Alonso Farto J . (123)I-mIBG scintigraphy in patients with known or suspected neuroblastoma: Results from a prospective multicenter trial. Pediatr Blood Cancer. 2009; 52(7):784-90. DOI: 10.1002/pbc.21932. View